Comparative effects of different doses of ribavirin plus interferon-α2b for therapy of chronic hepatitis C -: Results of a controlled, randomized trial

被引:23
作者
Bonkovsky, HL
Stefancyk, D
McNeal, K
Banner, BF
Liu, Q
Zucker, GM
Israel, J
Stagias, J
Colker, J
机构
[1] Univ Massachusetts, Sch Med, Liver Biliary Pancreat Ctr, Worcester, MA 01655 USA
[2] Univ Massachusetts, Sch Med, Div Digest Dis & Nutr, Worcester, MA 01655 USA
[3] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA
[4] Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA
[5] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA
[6] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA
[7] Cooley Dickenson Hosp, Northampton, MA USA
[8] Hartford Hosp, Hartford, CT 06115 USA
[9] Univ Connecticut, Sch Med, Storrs, CT 06268 USA
[10] Harrington Hosp, Southbridge, MA USA
[11] Berkshire Med Ctr, Pittsfield, MA USA
关键词
hepatitis C; interferon-alpha(2b); ribavirin; hepatic histopathology; adverse events; anemia;
D O I
10.1023/A:1011919906194
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Compared to either drug alone, therapy with the combination of ribavirin and interferon-a leads to improved rates of response in patients with chronic hepatitis C. Side effects often mandate downward dose adjustment or cessation of therapy, and the optimal dose of ribavirin has not been established. The aim of this study was to learn whether 600 mg ribavirin per day would prove as efficacious as 1000-1200 mg/day when combined with interferon (3 million units thrice weekly) for therapy of patients previously treated with standard interferon who had failed to respond or who had relapsed. We enrolled 69 patients with chronic hepatitis C and compensated liver disease: 45 were men, 65 were Caucasian, 48 were infected with genotype 1 hepatitis C virus. By random assignment, 35 received 600 mg ribavirin/day (group A), whereas the other 34 received 1000 mg (less than or equal to 75 kg body wt) or 1200 mg/day (> 75 kg body wt) (group B). At baseline, the two groups were well matched for demographic and laboratory features. In both groups, mean serum levels of alanine aminotransferase (ALT) and hepatitis C viral (HCV) RNA levels fell promptly and remained significantly lower than baseline throughout 24 weeks of therapy. There was no significant difference in mean levels of ALT or HCV RNA during therapy or at the end of follow-up (24 weeks after cessation of therapy). At the end of 24 weeks of posttherapy follow-up, 12 patients in each group had undetectable HCV RNA in serum, whereas 11 (31%) in group A and 9 (26.5%) in group B had normal serum ALT levels. The lower doses of ribavirin (group A) were tolerated better. In conclusion, in previous nonresponders or relapsers to interferon done, combination therapy with interferon-alpha (2b) (3 MU thrice weekly) + 600 mg ribavirin/day is tolerated better and is as effective as interferon plus higher (standard) doses of ribavirin (1000-1200 mg/day).
引用
收藏
页码:2051 / 2059
页数:9
相关论文
共 24 条
[1]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[2]  
ALTER MJ, 1997, HEPATOLOGY S1, V26, P62
[3]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[4]   Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial [J].
Bodenheimer, HC ;
Lindsay, KL ;
Davis, GL ;
Lewis, JH ;
Thung, SN ;
Seeff, LB .
HEPATOLOGY, 1997, 26 (02) :473-477
[5]   Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy [J].
Bonkovsky, HL ;
Woolley, JM .
HEPATOLOGY, 1999, 29 (01) :264-270
[6]   Iron and chronic viral hepatitis [J].
Bonkovsky, HL ;
Banner, BF ;
Rothman, AL .
HEPATOLOGY, 1997, 25 (03) :759-768
[7]  
Bonkovsky HL, 1999, HEPATOLOGY, V30, p265A
[8]  
BONKOVSKY HL, 1997, HEPATOLOGY S1, V26, P143
[9]  
BONKOVSKY HL, 2000, IN PRESS CAN J GASTR
[10]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506